Methyl furan-3-carboxylate Pharma Grade API, a low-molecular-weight furan-3-carboxylic acid ester with molecular weight 126.11 g/mol, is handled as a neutral, low-dose active in oral solid finished dosage forms. Direct compression is evaluated first when the intended tablet strength is 0.5–10 mg per unit and the API content is 0.5–2.0% w/w. Jet milling is applied to reduce the as-received particle size to a laser-diffraction volume median Dv50 of 5–15 µm and Dv90 below 30 µm, measured according to USP <429>. The milled material is pre-blended with 10–20% of the total microcrystalline cellulose PH102 charge in a 200–600 L bin blender at 12–15 RPM for 10 minutes. The pre-blend is passed through a 500 µm sieve and returned to the blender with the remaining microcrystalline cellulose, crospovidone 2–5% w/w, and colloidal silicon dioxide 0.5–1.5% w/w. Main blending continues for 20 minutes at 15 RPM. Magnesium stearate 0.25–0.75% w/w is added last and blended for 3–5 minutes. Blend uniformity sampling at 10–20 positions must yield an individual content RSD ≤5% before compression. Bulk powder loss on drying is controlled at ≤0.5% before mixing; if warehouse RH exceeds 60%, excipient pre-drying at 40–50°C for 2 hours is applied before use. A rotary tablet press with 8–10 mm round tooling is set to compress to 5–10 kp hardness and friability ≤0.8% per USP <1216>. Tablets are tested for content uniformity per USP <905> with an acceptance value AV ≤15.0 and disintegration per USP <701> with a limit of NMT 5 minutes. Dissolution testing per USP <711> uses Apparatus 2 at 50 RPM in a medium selected during development; if solubility is low, 0.1 N HCl with 0.5% SLS or a pH 4.5 acetate buffer is screened. Excipients containing primary or secondary amine groups are excluded from the initial direct compression matrix because the ester carbonyl can undergo aminolysis; binary mixture compatibility is screened at 40°C/75% RH for 4 weeks per ICH Q1A(R2). In-process sampling and testing are executed per 21 CFR 211.110. Published production-scale batch data specific to methyl furan-3-carboxylate direct compression are limited; the stated process boundary is a platform range for neutral low-dose furan ester APIs and must be confirmed by ICH Q1A(R2) stress and pilot-scale runs.

What process window prevents ester hydrolysis during aqueous binder addition?

In high-shear granulation equipment with a working volume of 100–600 L, aqueous binder systems can be used only when the binder pH is maintained at 4.0–5.5 and the mass temperature is kept at 20–25°C. Methyl furan-3-carboxylate contains a furan-3-carboxylate ester that is susceptible to ester cleavage under sustained alkaline or strongly acidic aqueous conditions; published kinetic constants for the exact compound are limited, so the pH window is verified by stress testing per ICH Q1A(R2). A typical early development formula uses 1–5% w/w API, 60–75% w/w lactose monohydrate, 10–20% w/w microcrystalline cellulose, 3–5% w/w croscarmellose sodium, and 4–6% w/w granulating solution solids of hydroxypropylcellulose or povidone K30. The binder solution is prepared at 20–25°C and adjusted to pH 4.0–5.5 with dilute hydrochloric acid or sodium hydroxide. The solution viscosity at 25°C is controlled at 5–15 mPa·s for a 4–6% HPC system. Granulation proceeds at an impeller speed of 200–300 RPM and chopper speed of 1000–1500 RPM; wet massing time is limited to 2–4 minutes to avoid over-wetting. Spray atomization is operated at 1.0–2.0 bar air pressure. The wet granules are dried in a fluid-bed dryer with inlet air at 50–60°C and product temperature 30–40°C until loss on drying is 1.5–2.5%. Dried granules are milled through a 0.8–1.2 mm screen; the target granule fraction 125–250 µm should exceed 60% by sieve analysis per USP <786>. Compression is performed with 10–12 mm round or oval tooling at 8–18 kN force; tablet hardness 8–15 kp and friability ≤0.5% are controlled. Film coating with aqueous Opadry II at a target weight gain of 2–3% w/w is applied in a side-vented pan at 45–55°C inlet air and 15–25 RPM pan speed. The coated tablets are tested for content uniformity per USP <905> and dissolution per USP <711>. If the granulation endpoint drifts above pH 6.0 or moisture exceeds 2.5%, ester hydrolysis may increase and a stability batch should be placed on ICH Q1A(R2) accelerated testing at 40°C/75% RH. The described ranges are derived from common low-dose ester APIs; methyl furan-3-carboxylate-specific design space confirmation requires DoE runs at pilot scale.

Capsule filling of methyl furan-3-carboxylate at fill weights below 120 mg is governed by powder flow, static charge, and moisture ingress rather than direct pressure. The formulation is dry-blended at 20–25°C and relative humidity ≤40% RH. A representative blend includes 0.5–2.0% w/w milled API, 70–80% w/w lactose monohydrate with a Dv50 of 90–150 µm, 10–15% w/w pregelatinized starch or microcrystalline cellulose, 2–4% w/w sodium starch glycolate, 1–2% w/w talc, and 0.5% w/w magnesium stearate. The API is first geometrically diluted with lactose monohydrate in a low-shear tumble blender for 10 minutes; the pre-blend is screened through a 600 µm mesh. Final blending is conducted in a 300–1000 L bin blender at 12–15 RPM for 15–20 minutes. Powder flow is measured by Ph. Eur. 2.9.36; a Carr index of 15–25% and Hausner ratio of 1.15–1.35 are targeted for consistent tamping-pin capsule fillers. Equipment used includes Bosch GKF or MG2 tamping-pin machines with 0–4 pin stations adjusted to produce slug densities of 0.6–0.8 g/mL and pin penetration of 4–6 mm. Hard gelatin or HPMC capsule shells are selected with a shell moisture specification of 13–16% for gelatin and 3–7% for HPMC; filling is performed at ≤40% RH to prevent shell deformation and API hygroscopicity. The filled capsule weight is monitored at ±5% of target, and content uniformity per USP <905> is performed on 10 capsules. Dissolution testing per USP <711> is conducted with Apparatus 2 at 50 RPM; capsule sinks are used if floating is observed. If the API is milled to a Dv90 below 30 µm, electrostatic adhesion to capsule shells may increase; controlled humidity and talc addition at 1–2% w/w reduce this failure mode. Capsules are packed in HDPE bottles with desiccant canisters and sealed with induction-sealed caps; long-term stability is monitored per ICH Q1A(R2) at 25°C/60% RH and intermediate 30°C/65% RH. Published production-scale data for methyl furan-3-carboxylate capsule filling are limited; the above parameter set is a platform bracket for neutral, low-dose furan ester APIs.

Table 1. Representative formulation and process boundary ranges for low-dose methyl furan-3-carboxylate oral solid development.

Low-dose stick packs shift segregation thresholds during roller-compacted granule filling.

Low-dose oral granules in stick packs require segregation-resistant carrier particles and a filling line with vacuum-assisted form-fill-seal technology. Methyl furan-3-carboxylate is blended at 0.1–1.0% w/w with sorbitol, mannitol, or lactose monohydrate as the main carrier; xylitol or sucralose is included for patient acceptability, but no published organoleptic data for methyl furan-3-carboxylate were identified. A roller compactor with 50–100 kN roll force and a 2–4 mm screen is used to convert the powder blend to granules with a particle size distribution of 180–425 µm. Dry granulation avoids aqueous binder contact and thereby reduces the risk of ester hydrolysis; this is preferred when the API has demonstrated moisture sensitivity in ICH Q1A(R2) stress testing. The granule fraction below 75 µm is limited to NMT 15% to prevent segregation during stick pack filling. The granule bulk density is controlled at 0.5–0.7 g/mL. Flowability is controlled by Ph. Eur. 2.9.36 with a target Carr index of 15–25% and an orifice flow rate of 10–30 g/s through a 10 mm orifice. Stick pack filling is performed on horizontal form-fill-seal machines at 20–25°C and ≤35% RH using aluminum foil laminate film. Fill weight targets of 500–2000 mg are monitored with a mass standard deviation ≤2.5% of target. Content uniformity of the filled sachets is tested per USP <905> on 10 sachets with an AV ≤15.0. Loss on drying of the finished granules is controlled at ≤1.0% by Karl Fischer titration per USP <921>. Dissolution or dispersibility testing of granules may be performed per USP <711> or a compendial granule release method, depending on the regulatory filing. The segregation threshold is evaluated by sampling the hopper at the beginning, middle, and end of the filling run; the API content difference across these samples should not exceed 5% absolute. The described roller compaction and filling parameters are platform ranges for neutral low-dose oral granule systems; confirmation for methyl furan-3-carboxylate requires a design-of-experiment study at production scale.

When terminal moist heat sterilization is not feasible for furan ester solutions

Parenteral solutions of methyl furan-3-carboxylate are processed by aseptic filtration when ICH Q1A(R2) stress testing demonstrates more than 5% degradation at 121°C for 15 minutes or when the pH-dependent hydrolysis rate in the chosen buffer exceeds the acceptance threshold. A development formulation may contain 1–20 mg/mL API in a citrate or acetate buffer at pH 4.5–5.5 with 0.9% sodium chloride or 5% dextrose as tonicity adjuster. The pH is selected to minimize ester cleavage and furan ring oxidation; accelerated stability testing for the aqueous parenteral is conducted at 40°C/25% RH and 25°C/60% RH per ICH Q1A(R2). Compounding is performed in a closed stainless-steel vessel with bottom-mounted impeller and nitrogen sparge. The solution is blanketed with nitrogen; headspace oxygen in filled vials is controlled below 2% v/v where oxidative degradation is demonstrated. The bulk solution is passed through a 0.45 µm pre-filter and then through two 0.22 µm PVDF or polyethersulfone filters in series at 10–30 psi. Filter compatibility studies follow PDA Technical Report No. 26 and filter manufacturer bacterial retention validation; extractables and leachables are assessed per USP <1663> and USP <1664>. Filling is performed in an ISO 14644-1:2015 Class 5 aseptic environment with a maximum particle concentration of 3,520 particles per cubic metre at ≥0.5 µm. Filled vials are sealed with 13 mm or 20 mm elastomeric closures and aluminum flip-off caps. Subvisible particulate matter is tested per USP <788> or Ph. Eur. 2.9.19 with limits of NMT 6000 particles per container at ≥10 µm and NMT 600 particles per container at ≥25 µm. Sterility testing per USP <71> and bacterial endotoxin testing per USP <85> are performed; the endotoxin limit is product-specific and calculated from the maximum dose per kg. Strong oxidizing agents are excluded from the formulation and cleaning sequence because furan ring oxidation may occur. If the solution exhibits pH drift or visible precipitation after 24 hours at 25°C, the buffer molarity and cosolvent level are re-evaluated. Published stability data specific to methyl furan-3-carboxylate parenteral solutions are limited; the above filtration and filling envelope is a platform for low-molecular-weight furan ester injectables and requires compound-specific validation.

Residual moisture, cake structure, and reconstitution time in lyophilized furan ester vials

Freeze-drying of methyl furan-3-carboxylate in 10 mL Type I glass vials requires a cycle that avoids droplet collapse and maintains residual moisture below 1.0% where the ester is moisture-sensitive. The pre-lyophilization solution is formulated with 2–5% w/w mannitol or 2–10% w/w trehalose as cryoprotectant and citrate buffer 10–25 mM at pH 4.5–5.5. The filling volume is 2–5 mL per vial; vial load depth is controlled to 10–15 mm to permit uniform heat transfer. The lyophilization cycle in a production freeze dryer begins with shelf cooling to -40°C at 0.5–1.0°C/min. Freezing is held for 2–4 hours. An annealing step at -15°C for 2–3 hours may be applied to crystallize mannitol and reduce primary drying resistance. Primary drying is performed at a shelf temperature of -20°C to -10°C and chamber pressure of 100–200 mTorr for 20–40 hours; product temperature is monitored by thermocouples and must remain below the collapse temperature. Secondary drying is run at 25–40°C for 4–8 hours at 50–100 mTorr. The resulting cake is visually inspected for collapse, meltback, and ejection. Residual moisture is determined by Karl Fischer titration per USP <921> with a target of NMT 1.0% w/w. Reconstitution time with 5 mL water for injection is targeted at NMT 2 minutes; particulates after reconstitution are tested per USP <788>. Container closure integrity is verified by USP <1207> dye ingress or vacuum decay with a pass criterion of no dye entry or pressure loss below the method limit. The lyophilization process is validated with production-scale batch size and chamber load; published transfer-optimization data for methyl furan-3-carboxylate are limited, so cycle parameters are derived from low-molecular-weight ester parenteral formulations and standard freeze-dryer engineering profiles.

Table 2. Compliance matrix for methyl furan-3-carboxylate pharmaceutical applications.